atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round

atai Life Sciences, a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for various mental health indications, today announced the successful closing of its $157 million Series D financing round. The round was led by our existing investors Apeiron Investment Group, the family office of atai’s founder Christian Angermayer, Thiel Capital, and joined by Woodline Partners LP.